Source study found

Story checked

Anti-cancer molecules show promise in the fight against malaria (opens in a new tab)

medicalxpress.com · 2026-09-29

Short answerEvidenceSource

Short answer

Not supported

Not supported.

2 claims go further than the study. 2 other points were not covered by the paper.

2 overstated
2 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail

The story

Anti-cancer molecules show promise in the fight against malaria

medicalxpress.com · 2026-09-29

The story’s checkable claims.

Read the original story

NewsLink checks it

Not supported

Two of four claims overstate the study. Two claims the study doesn't address.

2 overstated
2 not covered

Open claim evidence

The source study

Repurposing 6‑Anilinopurine Derivatives That Exhibit PfHDAC1 Inhibition and Antimalarial Activity against Asexual and Sexual Stages of Plasmodium falciparum.

ACS Omega · 2026Open access

Open source record Open in Tessa

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

Reading mode

Scan verdicts. Open evidence only when needed.

Browse by verdict

4 claims in this story

Showing all 4 claimsChoose a verdict to focus the list.

Claim 1 of 4OverstatedMolecules known for their anticancer activity have proven effective against Plasmodium falciparum, the parasite that causes malaria.View evidenceHide evidence

Why this verdict

The abstract supports in vitro antiplasmodial activity of repurposed anticancer-associated 6-anilinopurine derivatives against asexual stages and gametocytes. But the headline wording says the molecules have 'proven effective' against P. falciparum without the in vitro qualifier or therapeutic caveats, so it outruns both the paper evidence and the story body's caveats about no in vivo testing.

Study evidence

6‑Anilinopurine derivatives show nanomolar in vitro potency against asexual blood stages of Plasmodium falciparum, active against both wild-type and chloroquine‑resistant strains.nanomolar potency (reported)

“compounds exhibit nanomolar activity against the asexual stages of Plasmodium falciparum wild-type and chloroquine-resistant strains in vitro”

Study evidence

13 of 14 6‑anilinopurine derivatives tested showed gametocidal activity after 48 h in vitro treatment.13/14 compounds active

“13 out of 14 compounds tested showed gametocidal activity after 48 h treatment”

Claim 2 of 4OverstatedFourteen compounds derived from an antineoplastic drug were tested on P. falciparum parasites cultured in the laboratory, and the molecules eliminated the parasites at both the asexual and gametocyte stages.View evidenceHide evidence

As statedfourteen compounds

Why this verdict

The abstract supports testing a 14-compound panel in laboratory parasite assays, with nanomolar in vitro activity against asexual stages and gametocidal activity for 13 of 14 compounds after 48 h. The claim overstates the result by saying the molecules 'eliminated' parasites at both stages and by implying all 14 did so at the gametocyte stage.

Study evidence

“compounds exhibit nanomolar activity against the asexual stages of Plasmodium falciparum wild-type and chloroquine-resistant strains in vitro”

Study evidence

13 of 14 6‑anilinopurine derivatives tested showed gametocidal activity after 48 h in vitro treatment.13/14 compounds active

“13 out of 14 compounds tested showed gametocidal activity after 48 h treatment”

Claim 3 of 4Not coveredThe research published in July in ACS Omega also investigated how differences in molecular structure affect activity and identified histone deacetylase enzymes as an important therapeutic target for malaria.View evidenceHide evidence

Why this verdict

The HDAC-target component is broadly consistent with the abstract, which attributes activity to inhibition of P. falciparum HDAC1. However, the supplied abstract-level profile does not verify the ACS Omega publication timing or the claimed investigation of how molecular structural differences affected activity. The story's quoted, hedged target-language is more defensible than a strong claim that the work 'identified' HDAC enzymes as a therapeutic target.

Study evidence

The authors attribute the antimalarial activity of tested 6‑anilinopurine derivatives to inhibition of PfHDAC1.

“The activity of these compounds is attributed to the inhibition of P. falciparum HDAC1”

Claim 4 of 4Not coveredOnly in vitro tests have been conducted so far, so safety, side effects, and drug stability in vivo remain uncertain.View evidenceHide evidence

Why this verdict

The supplied abstract-level evidence shows the reported assays are in vitro and does not provide in vivo efficacy, safety, or toxicity information, so the uncertainty caveat is directionally appropriate. But at abstract depth, the profile cannot verify the stronger 'only tests conducted so far' claim for the full paper, and it does not mention in vivo drug stability.

Study evidence

“compounds exhibit nanomolar activity against the asexual stages of Plasmodium falciparum wild-type and chloroquine-resistant strains in vitro”

Study evidence

13 of 14 6‑anilinopurine derivatives tested showed gametocidal activity after 48 h in vitro treatment.13/14 compounds active

“13 out of 14 compounds tested showed gametocidal activity after 48 h treatment”

Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

The abstract reports nanomolar activity against both wild-type and chloroquine-resistant P. falciparum strains.
The story does not mention the resistant-strain comparison or the nanomolar potency characterization, both of which are material parts of the abstract-level finding.
From in vitro asexual-stage drug susceptibility assay
The abstract presents gametocidal activity as indicating transmission-blocking potential but does not report direct mosquito transmission assays.
The story does not clearly acknowledge that the transmission-related inference rests on in vitro gametocyte activity rather than direct mosquito transmission testing.
From In vitro gametocyte exposure (48 h)

4 things the story did carry across

The paper’s core efficacy evidence is in vitro activity of repurposed 6-anilinopurine derivatives against asexual blood-stage P. falciparum.
The paper reports gametocidal activity after 48 h treatment, with 13 of 14 compounds active against sexual-stage parasites.
The paper attributes antimalarial activity mechanistically to inhibition of P. falciparum HDAC1.
The work is limited to in vitro evidence in the supplied profile, with no in vivo efficacy or safety evidence available at abstract depth.

Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

Evidence read

study summary

Lead result

in vitro

1Lead resultin vitroEvaluate repurposed 6‑anilinopurine derivatives for antimalarial potency against asexual blood stages of Plasmodium falciparum, including wild-type and chloroquine-resistant strains, in vitro.in vitro asexual-stage drug susceptibility assayExpand

In plain English

The abstract reports that repurposed 6‑anilinopurine derivatives block growth of asexual blood-stage Plasmodium falciparum in vitro with nanomolar potency, active against both wild-type and chloroquine-resistant strains.

Key findings

6‑Anilinopurine derivatives show nanomolar in vitro potency against asexual blood stages of Plasmodium falciparum, active against both wild-type and chloroquine‑resistant strains.nanomolar potency (reported)

“compounds exhibit nanomolar activity against the asexual stages of Plasmodium falciparum wild-type and chloroquine-resistant strains in vitro”

What this piece can’t prove

3 further details could not be confirmed from the summary.

2in vitroAssess whether these 6‑anilinopurine derivatives have transmission-blocking potential by killing/inhibiting sexual stages (gametocytes) of P. falciparum after 48 h treatment in vitro.In vitro gametocyte exposure (48 h)Expand

In plain English

The abstract reports that 13 of 14 tested 6‑anilinopurine derivatives exhibited gametocidal activity after 48 h in vitro treatment, which the authors present as indicating potential to inhibit parasite transmission.

Key findings

13 of 14 6‑anilinopurine derivatives tested showed gametocidal activity after 48 h in vitro treatment.13/14 compounds active

“13 out of 14 compounds tested showed gametocidal activity after 48 h treatment”

What this piece can’t prove

Abstract does not report direct mosquito transmission assays to confirm transmission-blocking beyond the in vitro gametocidal readout.

2 further details could not be confirmed from the summary.

3in vitroAttribute antimalarial activity mechanistically to inhibition of Plasmodium falciparum HDAC1 (PfHDAC1) by the tested compounds.Expand

In plain English

The paper reports that a series of 6‑anilinopurine derivatives show antimalarial activity in vitro and states that this activity is attributable to inhibition of Plasmodium falciparum histone deacetylase 1 (PfHDAC1). The abstract implies the authors performed target-based PfHDAC1 inhibition measurements distinct from whole-parasite assays, but provides no assay details or quantitative inhibition metrics in the abstract.

Key findings

The authors attribute the antimalarial activity of tested 6‑anilinopurine derivatives to inhibition of PfHDAC1.

“The activity of these compounds is attributed to the inhibition of P. falciparum HDAC1”

What this piece can’t prove

Abstract does not report which specific assays or controls were used to establish PfHDAC1 inhibition, nor whether orthogonal validation of target engagement was performed.

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer